We found that the promoting effect of LARS on the DLBCL malignant phenotypes, glycolysis-related proteins, and the glycolytic intermediates LA could be alleviated by the silenced LRPPRC. The gene discussed is LARS1; the disease is diffuse large B-cell lymphoma.